TSN 084
Alternative Names: TSN-084Latest Information Update: 28 Aug 2025
At a glance
- Originator Tyligand Bioscience
- Class Antineoplastics; Small molecules
- Mechanism of Action Cyclin dependent kinase 19 inhibitors; Cyclin-dependent kinase 8 inhibitors; Protein kinase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Aug 2025 No recent reports of development identified for phase-I development in Cancer(Late-stage disease, Metastatic disease) in China (PO, Tablet)
- 28 Apr 2025 No recent reports of development identified for phase-I development in Cancer(Late-stage disease, Metastatic disease) in USA (PO, Tablet)
- 13 Sep 2024 Efficacy, adverse events and pharmacokinetics data from a phase I trial in Cancer presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)